A 58-year-old man from rural Maharashtra presents with a 5-day history of fever, dysuria, and flank pain. He has diabetes mellitus (HbA1c 9.2%) and underwent a transurethral resection of prostate 2 weeks ago. On examination, he is febrile (38.8°C) with costovertebral angle tenderness. Urine culture grows a gram-negative rod. The organism is resistant to ceftriaxone, cefotaxime, and aztreonam, but susceptible to carbapenems and fluoroquinolones. The resistance is not reversed by clavulanic acid. What is the most likely resistance mechanism?

Explanation

## Clinical Scenario Analysis This patient presents with **urosepsis secondary to urinary tract infection** following a urological procedure. The urine culture shows a gram-negative rod with a specific resistance pattern that is diagnostically crucial. ## Resistance Pattern Interpretation **Key Point:** The organism is resistant to third-generation cephalosporins (ceftriaxone, cefotaxime) AND aztreonam, yet remains susceptible to carbapenems and fluoroquinolones. ### Pattern Differentiation | Feature | ESBL | AmpC | MBL | |---------|------|------|-----| | **Cephalosporin resistance** | Yes (3rd/4th gen) | Yes (3rd gen) | Yes (all) | | **Aztreonam resistance** | No (usually susceptible) | Yes | Yes | | **Carbapenem susceptibility** | Susceptible | Susceptible | **Resistant** | | **Clavulanic acid reversal** | Yes (inhibits) | No (not inhibited) | No (not inhibited) | **High-Yield:** The **resistance to aztreonam** is the critical discriminator. ESBLs do NOT typically hydrolyze aztreonam; AmpC enzymes DO. The **clavulanic acid non-reversal** rules out ESBL. The **carbapenem susceptibility** rules out MBL. ## AmpC Beta-Lactamase Mechanism 1. **Chromosomal or plasmid-encoded** serine beta-lactamase 2. **Broad substrate specificity:** hydrolyzes cephalosporins, cephamycins, monobactams (aztreonam), and beta-lactam/inhibitor combinations 3. **NOT inhibited** by clavulanic acid, sulbactam, or tazobactam 4. **Carbapenems remain effective** because they are poor substrates 5. **Common producers:** *Enterobacter*, *Citrobacter*, *Serratia*, *Providencia*, *Morganella*, *Acinetobacter* **Clinical Pearl:** AmpC-producing organisms are often associated with healthcare-acquired infections and prior beta-lactam exposure—this patient's recent TURP fits the epidemiology. ## Why Carbapenems Work Carbapenems have a **1-beta-methyl side chain** that sterically hinders AmpC enzyme access to the beta-lactam ring, making them poor substrates. This is why carbapenems are the drug of choice for AmpC-producing gram-negatives. **Mnemonic:** **ESCAP** — *Enterobacter, Serratia, Citrobacter, Acinetobacter, Providencia* — common AmpC producers. ## Treatment Implications **High-Yield:** For this patient with urosepsis: - **First-line:** Carbapenem (meropenem or imipenem) pending culture/susceptibility - **Alternative:** Fluoroquinolone (levofloxacin) if renal function permits - **Avoid:** Cephalosporins, aztreonam, beta-lactam/inhibitor combinations [cite:Mandell, Douglas, Bennett's Principles and Practice of Infectious Diseases 9e Ch 221]